RxSight, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by RxSight, Inc. on January 12, 2026, covering events occurring on January 11, 2026. The filing primarily addresses the appointment of a new Chief Financial Officer and references a press release containing preliminary unaudited financial results for the fourth quarter and full year 2025.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing preliminary unaudited results for Q4 and full-year 2025. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Management Commentary
Executive Leadership Change:
- Appointment: Mark Wilterding was appointed Chief Financial Officer (CFO), effective January 11, 2026.
- Predecessor: He replaces Shelley Thunen in the roles of CFO, principal financial officer, and principal accounting officer.
- Background: Mr. Wilterding previously served as Senior Vice President, Global Finance at Edwards Lifesciences (March 2025 – January 2026) and held various finance and investor relations roles at Edwards Lifesciences since 2019 and at Medtronic from 2014 to 2019.
Compensation and Equity Awards:
- Base Salary: $550,000 annually.
- Annual Bonus: Eligible for up to 65% of base salary.
- Sign-on Bonus: Amount to be determined per the Employment Agreement.
- Stock Options: Granted 258,770 options on January 12, 2026. Vesting schedule: 25% after one year, with the remainder vesting monthly over the subsequent three years.
- Restricted Stock Units (RSUs): Granted 163,528 RSUs. Vesting schedule: 1/8th on February 28, 2026, and 1/8th every six months thereafter over a four-year period.
Risks, Contingencies, and Unusual Items
The filing notes that the financial information referenced in Item 2.02 and the press release regarding the CFO appointment in Item 7.01 are furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor are they incorporated by reference into other filings unless expressly stated. No specific risks or contingencies were detailed in the text of this report beyond standard employment agreement terms.
Key Facts for Investor Verification
- Verify the specific Q4 and full-year 2025 financial results in the attached press release (Exhibit 99.1), as they are not detailed in this 8-K text.
- Confirm the exact amount of the sign-on bonus for the new CFO, as it is listed as "to be determined."
- Review the full text of the Employment Agreement and Severance Agreement, which are expected to be filed as exhibits in a subsequent periodic report.
- Monitor the transition of financial leadership from Shelley Thunen to Mark Wilterding effective January 11, 2026.